SUPPLEMENT

Q1 2020 — Sales of Key Products/Franchises

Q1 2020PDF · 6 pages168 KB
2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
BABY CARE
US 	92	$ 	87 	6.7% 	6.7% 	-
Intl 	269 	307 	-12.4% 	-8.2% 	-4.2%
WW 	361 	394 	-8.2% 	-4.9% 	-3.3%
SKIN HEALTH / BEAUTY(4)
US 	659 	588 	12.1% 	12.1% 	-
Intl 	458 	502 	-8.8% 	-6.5% 	-2.3%
WW 	1,117 	1,090 	2.5% 	3.5% 	-1.0%
ORAL CARE
US 	176 	151 	16.2% 	16.2% 	-
Intl 	219 	216 	1.5% 	5.3% 	-3.8%
WW 	395 	367 	7.6% 	9.8% 	-2.2%
OTC
US 	689 	507 	35.9% 	35.9% 	-
Intl 	659 	580 	13.7% 	17.0% 	-3.3%
WW 	1,348 	1,087 	24.1% 	25.8% 	-1.7%
WOMEN'S HEALTH
US 	4 	3 	32.0% 	32.0% 	-
Intl 	228 	222 	2.5% 	8.9% 	-6.4%
WW 	232 	225 	2.9% 	9.2% 	-6.3%
WOUND CARE / OTHER
US 	119 	102 	17.0% 	17.0% 	-
Intl 	52 	53 	-1.2% 	1.9% 	-3.1%
WW 	171 	155 	10.7% 	11.8% 	-1.1%
TOTAL CONSUMER HEALTH
US 	1,740 	1,438 	21.0% 	21.0% 	-
Intl 	1,885 	1,880 	0.3% 	3.9% 	-3.6%
WW 	3,625	$ 	3,318 	9.2% 	11.3% 	-2.1%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change

-- 1 of 6 --

2020 	2019 	Reported 	Operational (1) Currency
PHARMACEUTICAL SEGMENT (2)
IMMUNOLOGY
US 	2,410	$ 	2,163 	11.4% 	11.4% 	-
Intl 	1,228 	1,088 	12.8% 	16.3% 	-3.5%
WW 	3,638 	3,251 	11.9% 	13.1% 	-1.2%
REMICADE
US 	625 	774 	-19.3% 	-19.3% 	-
US Exports (5) 110 	76 	44.3% 	44.3% 	-
Intl 	256 	252 	1.5% 	5.2% 	-3.7%
WW 	990 	1,102 	-10.2% 	-9.3% 	-0.9%
SIMPONI / SIMPONI ARIA
US 	272 	263 	3.4% 	3.4% 	-
Intl 	258 	261 	-1.2% 	2.6% 	-3.8%
WW 	529 	524 	1.1% 	3.0% 	-1.9%
STELARA
US 	1,217 	882 	37.9% 	37.9% 	-
Intl 	603 	523 	15.2% 	18.3% 	-3.1%
WW 	1,819 	1,405 	29.5% 	30.6% 	-1.1%
TREMFYA
US 	187 	168 	11.5% 	11.5% 	-
Intl 	109 	49 	* 	* 	*
WW 	296 	217 	36.4% 	37.3% 	-0.9%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	-
Intl 	3 	3 	-6.9% 	-5.6% 	-1.3%
WW 	3 	3 	-6.9% 	-5.6% 	-1.3%
INFECTIOUS DISEASES
US 	436 	357 	22.3% 	22.3% 	-
Intl 	483 	489 	-1.2% 	2.7% 	-3.9%
WW 	920 	846 	8.7% 	11.0% 	-2.3%
EDURANT / rilpivirine
US 	12 	12 	0.6% 	0.6% 	-
Intl 	212 	199 	6.4% 	9.2% 	-2.8%
WW 	224 	211 	6.1% 	8.7% 	-2.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	396 	315 	25.5% 	25.5% 	-
Intl 	184 	208 	-11.6% 	-6.4% 	-5.2%
WW 	579 	523 	10.8% 	12.8% 	-2.0%
OTHER INFECTIOUS DISEASES
US 	29 	30 	-3.4% 	-3.4% 	-
Intl 	87 	82 	6.7% 	10.2% 	-3.5%
WW 	116 	112 	4.0% 	6.6% 	-2.6%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change

-- 2 of 6 --

2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	748 	723 	3.3% 	3.3% 	-
Intl 	910 	905 	0.5% 	3.0% 	-2.5%
WW 	1,658 	1,629 	1.8% 	3.1% 	-1.3%
CONCERTA / Methylphenidate
US 	52 	97 	-46.1% 	-46.1% 	-
Intl 	118 	116 	1.5% 	3.6% 	-2.1%
WW 	171 	214 	-20.1% 	-19.0% 	-1.1%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	544 	483 	12.6% 	12.6% 	-
Intl 	339 	307 	10.3% 	13.2% 	-2.9%
WW 	883 	790 	11.7% 	12.9% 	-1.2%
RISPERDAL CONSTA
US 	76 	77 	-0.3% 	-0.3% 	-
Intl 	94 	102 	-8.7% 	-5.9% 	-2.8%
WW 	170 	179 	-5.1% 	-3.5% 	-1.6%
OTHER NEUROSCIENCE
US 	75 	66 	12.5% 	12.5% 	-
Intl 	360 	379 	-5.1% 	-3.1% 	-2.0%
WW 	435 	446 	-2.5% 	-0.8% 	-1.7%
ONCOLOGY
US 	1,175 	962 	22.1% 	22.1% 	-
Intl 	1,839 	1,556 	18.2% 	21.7% 	-3.5%
WW 	3,013 	2,518 	19.7% 	21.8% 	-2.1%
DARZALEX
US 	463 	352 	31.8% 	31.8% 	-
Intl 	474 	277 	70.9% 	76.8% 	-5.9%
WW 	937 	629 	49.0% 	51.6% 	-2.6%
ERLEADA (6)
US 	119 	58 	* 	* 	-
Intl 	24 	3 	* 	* 	*
WW 	143 	61 	* 	* 	*
IMBRUVICA
US 	432 	349 	23.9% 	23.9% 	-
Intl 	599 	435 	37.8% 	42.3% 	-4.5%
WW 	1,031 	784 	31.6% 	34.1% 	-2.5%
VELCADE
US 	- 	- 	- 	- 	-
Intl 	108 	263 	-59.0% 	-58.2% 	-0.8%
WW 	108 	263 	-59.0% 	-58.2% 	-0.8%
ZYTIGA / abiraterone acetate
US 	139 	185 	-25.2% 	-25.2% 	-
Intl 	552 	494 	11.7% 	14.3% 	-2.6%
WW 	690 	679 	1.6% 	3.5% 	-1.9%
OTHER ONCOLOGY(6)
US 	22 	18 	20.1% 	20.1% 	-
Intl 	82 	84 	-2.7% 	0.6% 	-3.3%
WW 	104 	102 	1.3% 	4.1% 	-2.8%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
% Change
FIRST QUARTER

-- 3 of 6 --

2020 	2019 	Reported 	Operational (1) Currency
PULMONARY HYPERTENSION
US 	486 	430 	13.0% 	13.0% 	-
Intl 	260 	226 	14.9% 	17.8% 	-2.9%
WW 	745 	656 	13.7% 	14.7% 	-1.0%
OPSUMIT
US 	229 	172 	33.0% 	33.0% 	-
Intl 	160 	133 	20.2% 	23.3% 	-3.1%
WW 	389 	306 	27.4% 	28.8% 	-1.4%
UPTRAVI
US 	212 	176 	20.7% 	20.7% 	-
Intl 	38 	22 	70.2% 	75.0% 	-4.8%
WW 	250 	198 	26.2% 	26.8% 	-0.6%
OTHER PULMONARY HYPERTENSION(6)
US 	44 	82 	-45.9% 	-45.9% 	-
Intl 	62 	71 	-12.4% 	-10.7% 	-1.7%
WW 	106 	152 	-30.4% 	-29.6% 	-0.8%
CARDIOVASCULAR / METABOLISM / OTHER
US 	806 	947 	-14.9% 	-14.9% 	-
Intl 	354 	398 	-11.0% 	-8.7% 	-2.3%
WW 	1,160 	1,345 	-13.8% 	-13.1% 	-0.7%
XARELTO
US 	527 	542 	-2.7% 	-2.7% 	-
Intl 	- 	- 	- 	- 	-
WW 	527 	542 	-2.7% 	-2.7% 	-
INVOKANA / INVOKAMET
US 	117 	154 	-23.6% 	-23.6% 	-
Intl 	58 	49 	18.6% 	20.9% 	-2.3%
WW 	175 	202 	-13.5% 	-12.9% 	-0.6%
PROCRIT / EPREX
US 	76 	148 	-48.5% 	-48.5% 	-
Intl 	79 	78 	0.4% 	1.9% 	-1.5%
WW 	155 	226 	-31.6% 	-31.0% 	-0.6%
OTHER
US 	85 	104 	-18.0% 	-18.0% 	-
Intl 	217 	271 	-19.7% 	-17.1% 	-2.6%
WW 	302 	374 	-19.2% 	-17.4% 	-1.8%
TOTAL PHARMACEUTICAL
US 	6,061 	5,582 	8.6% 	8.6% 	-
Intl 	5,073 	4,662 	8.8% 	12.0% 	-3.2%
WW 	11,134	$ 	10,244 	8.7% 	10.1% 	-1.4%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change

-- 4 of 6 --

2020 	2019 	Reported 	Operational (1) Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US 	365 	343 	6.6% 	6.6% 	-
Intl 	362 	389 	-6.9% 	-5.1% 	-1.8%
WW 	727 	732 	-0.6% 	0.4% 	-1.0%
ORTHOPAEDICS
US 	1,250 	1,318 	-5.2% 	-5.2% 	-
Intl 	788 	885 	-11.0% 	-8.5% 	-2.5%
WW 	2,038 	2,204 	-7.5% 	-6.5% 	-1.0%
HIPS
US 	206 	213 	-3.6% 	-3.6% 	-
Intl 	132 	148 	-11.2% 	-8.4% 	-2.8%
WW 	337 	361 	-6.7% 	-5.6% 	-1.1%
KNEES
US 	214 	223 	-4.2% 	-4.2% 	-
Intl 	130 	146 	-11.4% 	-8.9% 	-2.5%
WW 	343 	369 	-7.0% 	-6.1% 	-0.9%
TRAUMA
US 	407 	417 	-2.3% 	-2.3% 	-
Intl 	247 	268 	-8.0% 	-5.3% 	-2.7%
WW 	654 	685 	-4.5% 	-3.5% 	-1.0%
SPINE, SPORTS & OTHER(7)
US 	423 	465 	-8.9% 	-8.9% 	-
Intl 	280 	323 	-13.3% 	-11.1% 	-2.2%
WW 	703 	788 	-10.7% 	-9.8% 	-0.9%
SURGERY
US 	844 	1,001 	-15.7% 	-15.7% 	-
Intl 	1,257 	1,394 	-9.8% 	-6.7% 	-3.1%
WW 	2,100 	2,395 	-12.3% 	-10.5% 	-1.8%
ADVANCED
US 	381 	404 	-5.7% 	-5.7% 	-
Intl 	567 	576 	-1.6% 	1.6% 	-3.2%
WW 	948 	980 	-3.3% 	-1.4% 	-1.9%
GENERAL(6)
US 	463 	597 	-22.5% 	-22.5% 	-
Intl 	690 	818 	-15.7% 	-12.6% 	-3.1%
WW 	1,153 	1,414 	-18.5% 	-16.8% 	-1.7%
VISION
US 	439 	446 	-1.6% 	-1.6% 	-
Intl 	628 	682 	-8.0% 	-6.4% 	-1.6%
WW 	1,067 	1,129 	-5.5% 	-4.5% 	-1.0%
CONTACT LENSES / OTHER
US 	346 	321 	7.7% 	7.7% 	-
Intl 	467 	502 	-7.0% 	-5.4% 	-1.6%
WW 	814 	824 	-1.3% 	-0.3% 	-1.0%
SURGICAL
US 	93 	125 	-25.5% 	-25.5% 	-
Intl 	160 	180 	-11.0% 	-9.2% 	-1.8%
WW 	253 	305 	-16.9% 	-15.9% 	-1.0%
TOTAL MEDICAL DEVICES
US 	2,898 	3,109 	-6.8% 	-6.8% 	-
Intl 	3,034 	3,350 	-9.4% 	-6.9% 	-2.5%
WW 	5,932	$ 	6,459 	-8.2% 	-6.9% 	-1.3%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency 	(5) Reported as U.S. sales
(2) Unaudited 	(6) Refer to supplemental schedule
(3) Previously referred to as Consumer 	(7) Previously referred to as Spine & Other
(4) Previously referred to as Beauty
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures,
and therefore, may not recalculate precisely.
% Change

-- 5 of 6 --

Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
PHARMACEUTICAL SEGMENT (1)
ERLEADA(2)
US 	124 	58 	62 	74 	103 	297
Intl 	- 	3 	7 	12 	13 	35
WW 	124 	61 	69 	86 	116 	332
OTHER ONCOLOGY(2)
US 	104 	18 	16 	17 	19 	70
Intl 	362 	84 	85 	83 	84 	336
WW 	466 	102 	101 	100 	104 	407
Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
Pulmonary Hypertension
OTHER PAH(3)
US 	353 	82 	61 	36 	26 	205
Intl 	342 	71 	78 	61 	62 	272
WW 	695 	152 	140 	96 	88 	476
Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
MEDICAL DEVICES SEGMENT (1)
GENERAL SURGERY(4)
US 	2,468 	597 	530 	531 	534 	2,192
Intl 	3,431 	818 	794 	769 	834 	3,215
WW 	5,899 	1,414 	1,325 	1,301 	1,366 	5,406
Note: Columns and rows within tables may not add due to rounding.
(1) Unaudited
(2) ERLEADA was previously included in Other Oncology
(3) Other PAH is inclusive of TRACLEER, which was previously disclosed separately
(4) General Surgery is inclusive of Specialty Surgery, which was previously disclosed separately
Supplemental Schedule
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure ($MM)
2018 	2019
2018 	2019
2019
2019
2019
2018 	2019

-- 6 of 6 --